The use of monoclonal antibody-based ELISAs to monitor the efficacy of drugs against male Onchocerca gibsoni in vitro.

Four monoclonal antibodies directed against antigens of Onchocerca gibsoni were used in antigen detection ELISAs to monitor the efficacy of CGP 20309, CGP 20376, CGP 21833, CGP 24589 and CGP 26702 at 5 micrograms/ml against male O. gibsoni in vitro. No significant differences (P less than 0.05) in antigen output between treated and control groups of parasites were recorded. However, consistently higher levels of antigen from treated (CGP 21833) as compared to control parasites were measured with all four assays, with differences being higher in the first 2 to 3 days post treatment than subsequently. The sensitivity of comparisons between groups was reduced by the high variability in output of antigen both between worms and also from the same worm, in part as a result of mechanical damage to worms sustained during collection or manipulation in vitro. This problem was reduced by zero handling once worms were established in vitro and it is recommended that future work should include a 24 to 48 hour period before treatment commences to detect raised antigen levels associated with physically damaged parasites so they can be excluded. It was concluded that this type of assay has no intrinsic technical or logistical advantage over other published methods of assessing drug-related damage in in vitro filarial screens. Nevertheless, further work using antigen detection ELISAs in this context is justified since these assays, unlike all other methods of assessing drug-induced damage in vitro, have direct application for use in identifying chemotherapeutic effects against similar parasites in vivo.